Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6903478 | 0.85 | ALDH1A1 (0.44) | KMT2AMEN1SMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL6909266 | 0.83 | BTK (0.41) | KMT2AMEN1SMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL6907319 | 0.81 | IDO1 (0.51) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL6908564 | 0.78 | POLB (0.51) | KMT2AMEN1SMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL6909741 | 0.76 | LMNA (0.43) | KMT2AMEN1HPGDNPC1RAB9A | |
| SCHEMBL6905963 | 0.75 | POLB (0.47) | SMN1; SMN2GAA | |
| SCHEMBL18163286 | 0.75 | SMN1; SMN2 (0.60) | KMT2AMEN1SMN1; SMN2ALDH1A1ALOX15 | |
| SCHEMBL6908588 | 0.75 | LMNA (0.37) | KMT2AMEN1SMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL11496733 | 0.74 | MAPT (0.54) | KMT2AMEN1ALDH1A1HPGDNPC1 | |
| SCHEMBL7152781 | 0.74 | ALDH1A1 (0.48) | KMT2AMEN1SMN1; SMN2ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176496-A1 | Administering an antiproliferative agent in combination with a potentiating effective amount of a N- substituted dithiocarbamate ester or a pharmaceutically acceptable salt thereof | ATHEROGENICS, INC. (US) | 2003-09-18 | — | — | US | claimed |
| EP-1282445-A2 | N-SUBSTITUTED DITHIOCARBAMATES FOR THE TREATMENT OF BIOLOGICAL DISORDERS | Atherogenics, Inc. (US) | 2003-02-12 | — | — | EP | claimed |
| WO-2001079164-A2 | N-SUBSTITUTED DITHIOCARBAMATES FOR THE TREATMENT OF BIOLOGICAL DISORDERS | ATHEROGENICS, INC. (US) | 2001-10-25 | — | — | WO | claimed |
| US-6747061-B2 | ADMINISTERING AN ANTIPROLIFERATIVE AGENT IN COMBINATION WITH A POTENTIATING EFFECTIVE AMOUNT OF A N- SUBSTITUTED DITHIOCARBAMATE ESTER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ATHEROGENICS, INC. | 2004-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176496-A1 | Administering an antiproliferative agent in combination with a potentiating effective amount of a N- substituted dithiocarbamate ester or a pharmaceutically acceptable salt thereof | VCAM1, MKI67, SELL | KMT2A 1963/4885MEN1 1075/4885SMN1; SMN2 1130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.